rawpixel-shutterstock-com-4-1
Rawpixel / Shutterstock.com
29 October 2015AmericasCatherine Coombes

CRISPR: careless talk costs patents

The identification of the clustered regularly interspaced short palindromic repeat (CRISPR)/Cas9 system for gene editing of eukaryotes has led to an explosion of research in this area due to the far-reaching applications of the system. This in turn has led to a race to carve out valuable commercial protection for CRISPR/Cas9 and use of this system in various applications.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
29 January 2026   A judge has allowed antitrust claims against the pharma giant to move forward, finding that it plausibly used bundled rebates and patent abuse to extend its insulin monopoly, though one allegation was dismissed.
Americas
28 January 2026   The rise of fake online stores selling counterfeit pharmaceuticals is driving a surge in domain name disputes, forcing major brands to defend revenue and reputation.
Americas
27 January 2026   As quantum-enabled innovation accelerates, patentability will hinge on predictability, disclosure, and modality-specific claim drafting in an increasingly unforgiving enablement landscape, explain Ray Miller and Joseph Wolfe of DLA Piper